Viewing Study NCT02518594


Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2025-12-27 @ 11:19 PM
Study NCT ID: NCT02518594
Status: COMPLETED
Last Update Posted: 2025-09-05
First Post: 2015-03-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
Sponsor: The George Washington University Biostatistics Center
Organization:

Study Overview

Official Title: A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
Status: COMPLETED
Status Verified Date: 2025-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PROSPECT
Brief Summary: This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters.
Detailed Description: This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters.

Multiple gestation increases the risk of preterm delivery. Babies born preterm have increased rates of neonatal mortality and long-term neurodevelopmental morbidities. Short cervical length is known to be an important risk factor for spontaneous preterm birth and to occur more frequently in women with a twin gestation. Although there is no evidence that progesterone reduces the risk of preterm birth in multifetal gestation, there is evidence that progesterone reduces the risk of prematurity in singleton gestations complicated with a short cervix. The Arabin pessary has also been shown to reduce the risk of preterm birth among singletons with a short cervix, and in a secondary subgroup analysis of a recent study of the use of pessary in multiple gestations, women with a cervical length \< 25th percentile had a significantly reduced risk of the primary composite neonatal adverse outcome. Secondary analysis of studies of vaginal progesterone in multiple gestation with a short cervix also suggest a possible beneficial effect on preterm delivery.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
U24HD036801 NIH None https://reporter.nih.gov/quic… View
UG1HD087230 NIH None https://reporter.nih.gov/quic… View
UG1HD027869 NIH None https://reporter.nih.gov/quic… View
UG1HD027915 NIH None https://reporter.nih.gov/quic… View
UG1HD034208 NIH None https://reporter.nih.gov/quic… View
UG1HD040500 NIH None https://reporter.nih.gov/quic… View
UG1HD040485 NIH None https://reporter.nih.gov/quic… View
UG1HD053097 NIH None https://reporter.nih.gov/quic… View
UG1HD040544 NIH None https://reporter.nih.gov/quic… View
UG1HD040545 NIH None https://reporter.nih.gov/quic… View
UG1HD040560 NIH None https://reporter.nih.gov/quic… View
UG1HD040512 NIH None https://reporter.nih.gov/quic… View
UG1HD087192 NIH None https://reporter.nih.gov/quic… View
UG1HD112063 NIH None https://reporter.nih.gov/quic… View
UG1HD112092 NIH None https://reporter.nih.gov/quic… View
UG1HD112096 NIH None https://reporter.nih.gov/quic… View
UG1HD068282 NIH None https://reporter.nih.gov/quic… View
UG1HD068258 NIH None https://reporter.nih.gov/quic… View
UG1HD068268 NIH None https://reporter.nih.gov/quic… View